Session » Systemic Lupus Erythematosus – Animal Models Poster

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

Abstract Number: 2085

Response Gene to Complement-32 Promotes Kidney Damage in Immune Complex –Mediated Glomerulonephritis

Abstract Number: 2086

4-Phenylbutyric Acid Mediates Therapeutic Effect in Systemic Lupus Erythematosus: Observations in an Experimental Murine Lupus Model

Abstract Number: 2087

Kidney Tissue Damage in Mice with Single and Combined Abnormalities in Complement, Interferon and Apoptotic Cell Clearance

Abstract Number: 2088

Human TLR8 at the Interface between Innate and Adaptive Immunity in Systemic Lupus Erythematosus

Abstract Number: 2089

The Differential Impact of the Abrogation of the Costimulatory Molecule CD137 Ligand on Renal and Cerebral Manifestations in C57BL/6.Faslpr-/- mice

Abstract Number: 2090

Identification of a Role for Monocytes in Murine Lupus Associated Diffuse Alveolar Hemorrhage By Mass Cytometry

Abstract Number: 2091

Mucosal-Associated Invariant T (MAIT) Cells As a Potential Therapeutic Target for Systemic Lupus Erythematosus

Abstract Number: 2092

Glucocorticoid-Induced Leucine Zipper (GILZ) Is a Novel Checkpoint Regulator of Type I Interferon (IFN) Production in SLE

Abstract Number: 2093

Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency Worsens Autoimmunity in the Lyn-Deficient Murine Model of Lupus By Disinhibiting the Type I Interferon (IFN) Pathway

Abstract Number: 2094

Examining T Cell Exhaustion in Murine Systemic Lupus Erythematosus

Abstract Number: 2095

Neutralizing CXCL13 Attenuates Neuropsychiatric Disease in Lupus-Prone Mice

Abstract Number: 2096

Ectonucleotidase CD73 Suppresses Autoantibody Production and Arterial Vasculopathy in Murine Lupus

Abstract Number: 2097

Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease Severity and Alters Immune Cell Subsets in the NZB/W F1 Murine Model of Lupus

Abstract Number: 2098

NRF2 Downregulates Inflammation and Protects Against Autoimmune Lung Disease in Experimental Lupus

Abstract Number: 2099

Bruton’s Tyrosine Kinase (BTK) Inhibition Modulates Multiple Cell Types Instrumental in the Pathogenesis of Lupus Nephritis

Abstract Number: 2100

Topical Endocannabinoid Administration Protects MRL-Lpr/Lpr Mice from Cutaneous Lupus Erythematosus

Abstract Number: 2101

UV-Induced Skin Inflammation Is Exacerbated in Lupus-Prone Ro60 Knockout Female Mice with Interferon Priming

Abstract Number: 2102

Hyaluronic Acid Synthesis Inhibition Blocks Nephritis and Extends Lifespan in Mice Prone to Lupus

Abstract Number: 2103

Using a Drosophila Model to Unravel the Genetic Complexity of Systemic Lupus Erythematosus

Abstract Number: 2104

Glomerular and Tubular Transcriptional Profiles Reveal Gene Clusters Specific for Different Stages of Glomerulonephritis in NZM2328 Mice

Abstract Number: 2105

Genetic Analysis of a Drosophila Systemic Lupus Erythematosus Model Reveals Lupus Susceptibility Genes

Abstract Number: 2106

Angiotensin-Converting Enzyme Inhibitors Prevent Spatial Memory Impairment in a Mouse Model of Neuropsychiatric Lupus through LAIR1-Mediated Inhibition of Microglial Activation

Abstract Number: 2107

Lupus-Prone SLE1.2.3. Mice Exhibit Loss of Thymus-Derived CD4+CD25+Helios+ Tregs

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.